Assertio Holdings, Inc.

NASDAQ:ASRT

Drug Manufacturers - Specialty & Generic

Healthcare
$23.50 +0.04%

+$0.01 today

Market cap
$151.86M
Beta
0.53
P/E (TTM)
-4.2
EPS (TTM)
-$5.55
52W Low $8.61High $23.50

Volume 0.27M

Average 0.33M

ASRT Pre-Tax Margin

Income before tax as a percentage of revenue.

Assertio Holdings, Inc.NASDAQ: ASRT

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin narrows to -189.4%

Pre-tax margin was -189.4% in Q1 FY2026, down 139.2 pp from a year earlier. On a trailing-twelve-month basis it was -34.7%, down 9.1 pp year over year. Over 3 fiscal years it narrowed by 45.2 pp.

Context

  • Pre-tax margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-189.4%-102.6 pp QoQ
Last fiscal yearDec 2025
-25.2%-8.0 pp YoY
LTMMar 2026
-34.7%-9.1 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-139.2 pp——
1 year-8.0 pp——
3 years-45.2 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-25.2%
Year-over-year change
-8.0pp

Pre-Tax Margin vs competitors

How ASRT compares with its peers on the latest reported figures

  • ASRT's LTM Mar 2026 pre-tax margin of -34.7% is the 3rd highest of the 7 companies compared; the peer median is -48.4%.
  • Its year-over-year change of -9.1 pp is the 5th highest of 7, against a peer median of +71.0 pp.
  • Over three fiscal years its change of -45.2 pp compares with a peer median of +11.3 pp.
ASRT Competitors Peer median
Pre-Tax Margin for ASRT and competitors
Company Period LTM level YoY 3-year change
FBIOFortress Biotech, Inc.LTM Mar 2026201.4% +385.1 pp+228.8 pp
VXRTVaxart, Inc.LTM Mar 202614.7% +136.7 pp+100652.9 pp
ASRTAssertio Holdings, Inc.LTM Mar 2026-34.7% -9.1 pp-45.2 pp
INCRInterCure Ltd.LTM Jun 2025-37.5% -14.7 pp-27.6 pp
LUNGPulmonx CorporationLTM Mar 2026-59.4% +5.4 pp+50.2 pp
NTRBNutriband Inc.LTM Apr 2026-448.4% -32.6 pp-188.5 pp
TCRXTScan Therapeutics, Inc.LTM Mar 2026-1360.6% +1613.5 pp-767.6 pp
XBITXBiotech Inc.FY2025— ——
PMVPPMV Pharmaceuticals, Inc.FY2025— ——
ACRVAcrivon Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding ASRT) -48.4%+71.0 pp+11.3 pp

Competitors are the stored peer set for ASRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue111.01M156.23M152.07M124.96M118.71M
Cost of Revenue15.83M18.75M27.02M39.23M65.39M
Gross Profit95.18M137.49M125.05M85.73M53.33M
Gross Margin85.7%88.0%82.2%68.6%44.9%
Research & Development002.84M3.82M1.69M
Selling, General & Admin56.56M48.1M69.74M76.95M68.86M
Operating Expenses85.76M98.08M368.59M110.21M70.55M
Depreciation & Amortization29.11M33.4M28.23M25.83M30.01M
EBITDA38.78M90.17M53.17M5.15M3.14M
EBITDA Margin34.9%57.7%35.0%4.1%2.6%
Operating Income9.42M39.41M(243.54M)(24.48M)(17.22M)
Operating Margin8.5%25.2%-160.1%-19.6%-14.5%
Interest Income0003.22M2.67M
Interest Expense10.22M7.96M3.38M3.04M3.08M
Other Income / Expenses(9.98M)(8.24M)(10.52M)2.95M(12.72M)
Income Before Tax(553K)31.17M(254.05M)(21.53M)(29.94M)
Pre-Tax Margin-0.5%19.9%-167.1%-17.2%-25.2%
Income Tax Expense728K(78.46M)77.89M52K435K
Net Income(1.28M)109.63M(331.94M)(21.58M)(30.38M)
Net Margin-1.2%70.2%-218.3%-17.3%-25.6%
EPS (Basic)(0.45)34.95(70.05)(3.45)(4.74)
EPS (Diluted)(0.45)30.45(70.05)(3.45)(4.74)
Weighted Avg Shares2.88M3.13M4.74M6.35M6.4M
Weighted Avg Shares (Diluted)2.88M3.64M4.74M6.35M6.4M

Assertio Holdings, Inc.

NASDAQ:ASRT

Intrinsic Alpha fair value

Locked

Current Price

$23.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.